Deutsche Bank cuts Schott Pharma stock to Hold and raises target to EUR 25.00

Published on 10/20/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue reached EUR 281.80 million, up 8.30 percent year over year. Schott Pharma stock costs EUR 25.48 on October 20, 2026 versus EUR 25.50 Xetra close.

Analyst target and company growth

Deutsche Bank changed its rating on October 9, 2026 and set a EUR 25.00 target.
Revenue reached EUR 281.80 million in the third quarter of fiscal 2026, up 8.30 percent year over year.
Schott Pharma stock trades at EUR 25.48 at 12:43 p.m. CEST at Lang & Schwarz on October 20, 2026, 0.08 percent below the Xetra close of October 19, 2026.
Fiscal 2026 results are scheduled for December 10, 2026.

Bauhaus-Poster mit geometrischen Formen und Glasfläschchen-Motiven — SCHOTT Pharma (DE000A3ENQ51) inspiriert ein Bauhaus-Poster mit geometrischen Formen, bunten Glasfläschchen und dem Schriftzug PHARMA, Illustration mit AI erstellt.

Schott Pharma (ISIN DE000A3ENQ51) is trading at EUR 25.48 at Lang & Schwarz on October 20, 2026 at 12:43 p.m. CEST, 0.08 percent below the Xetra close of October 19, 2026 at EUR 25.50. Deutsche Bank Research cut its rating from Buy to Hold and raised its price target from EUR 23.00 to EUR 25.00 on October 9, 2026, according to Head Topics.

Revenue growth meets margin pressure

The latest operating picture combines solid sales growth with lower profitability. In the third quarter of fiscal 2026, revenue reached EUR 281.80 million, up 8.30 percent at constant currencies and 10.00 percent on a reported basis, while EBITDA was EUR 75.00 million and the margin was 26.80 percent, according to Yahoo Finance. The comparison is demanding because the margin was 32.30 percent in the year-earlier quarter.

For the first nine months of fiscal 2026, revenue was EUR 769.80 million, up 4.10 percent as reported, while net income fell 9.00 percent year over year to EUR 103.40 million. Management confirmed fiscal 2026 revenue growth guidance of 5.00 to 6.00 percent at constant currencies and an EBITDA margin range of 27.00 to 28.00 percent in the same call.

What does the target imply?

Deutsche Bank's EUR 25.00 target is 1.88 percent below the Lang & Schwarz price of EUR 25.48, so the rating change is more cautious than the target adjustment. The counterweight is execution: DDS EBITDA fell 16.30 percent in the first nine months, while DCS EBITDA increased 10.10 percent to EUR 109.70 million, according to Yahoo Finance.

Three dates frame the next move

On July 8, 2026, SCHOTT Pharma raised fiscal 2026 revenue growth guidance to 5.00 to 6.00 percent from 2.00 to 5.00 percent, as described in Yahoo Finance. On August 12, 2026, it reported third-quarter revenue of EUR 281.80 million. On October 9, 2026, Deutsche Bank moved the rating to Hold and lifted the target to EUR 25.00, as reported by Head Topics.

Upcoming investor dates

SCHOTT Pharma's investor-relations calendar lists the BNP Midcap CEO Conference for November 17, 2026 and the LBBW German Company Day for November 18, 2026. The company is scheduled to publish fiscal 2026 results on December 10, 2026, according to its SCHOTT Pharma investor-relations page.

Price stays near the yearly high

The stock remains EUR 0.57 below its 52-week high of EUR 26.05 and EUR 12.86 above its 52-week low of EUR 12.62, based on the same October 20, 2026 market snapshot. That valuation leaves the December results as the next major test for whether revenue growth can translate into the guided margin range.

Schott Pharma was trading at EUR 25.48 at Lang & Schwarz on October 20, 2026 at 12:43 p.m. CEST, minus 0.08 percent versus the Xetra close of October 19, 2026 at EUR 25.50. The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.